Q2 Earnings Forecast for TG Therapeutics Issued by B. Riley

TG Therapeutics, Inc. (NASDAQ:TGTX) has caught the attention of analysts, particularly those at B. Riley, who recently released their earnings forecast for the company’s Q2 2025. In a research report published on March 4th, 2025, analyst M. Mamtani projected that TG Therapeutics will achieve earnings of $0.27 per share during this quarter. This forecast stands in comparison to the consensus estimate for the company’s full-year earnings, which is currently set at $0.08 per share.

Furthermore, B. Riley has provided insights into TG Therapeutics' expected earnings for upcoming quarters as well. The estimates include Q3 2025 earnings of $0.26 per share, Q4 2025 earnings of $0.28 per share, and an overall FY2025 earnings projection of $1.03 per share. Looking further ahead, they anticipate earnings reaching $2.78 for FY2027, $3.85 for FY2028, and $4.74 for FY2029.

Recent Earnings Performance

In their most recent earnings announcement on March 3rd, TG Therapeutics released their quarterly results, reporting $0.15 earnings per share, which exceeded analysts' expectations of $0.08 by $0.07. The company also generated revenue of $108.19 million for the quarter, surpassing analyst predictions of $100.67 million. Despite this positive performance, TG Therapeutics noted a negative net margin of 5.42% and a negative return on equity of 8.32%.

Analyst Ratings and Stock Performance

In addition to B. Riley's report, other analysts have been reviewing TG Therapeutics. Notably, StockNews.com raised their rating from “sell” to “hold.” HC Wainwright reaffirmed a “buy” rating along with a target price of $55.00 for the company’s shares. Similarly, JPMorgan Chase & Co. increased their price target on TG Therapeutics from $30.00 to $43.00 while assigning an “overweight” rating. The overall reception from analysts is positive, with two rating the stock as a hold and five giving it a buy rating. Current consensus indicates a “Moderate Buy” rating, with an average price target of $40.67.

Current Stock Price and Market Overview

As of the last trading day, shares of TG Therapeutics opened at $35.19. The stock has experienced fluctuations, hitting a 12-month low of $12.93 and a high of $37.58. It has a market capitalization of $5.48 billion, a price-to-earnings ratio of -351.86, with a beta of 2.30. The company's liquidity positions are strong, reflected by a current ratio of 4.59 and a quick ratio of 3.91.

Insider Activity and Institutional Interests

In terms of insider trading, CFO Sean A. Power sold 11,337 shares on January 3rd for around $343,397.73. This transaction has reduced their ownership to an estimated 670,632 shares, valued at approximately $20.3 million. Insiders currently hold about 10.50% of TG Therapeutics’ stock.

Institutional investors have also been active concerning TG Therapeutics' shares. For instance, Arizona State Retirement System recently increased its stake by 0.9%, while Blue Trust Inc. grew its holding by 24.5%. Other investment management firms like Summit Investment Advisors and Private Advisor Group have also made strategic moves to increase their positions during the previous quarters, highlighting strong institutional interest in the company.

About TG Therapeutics

TG Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for B-cell mediated diseases. Their flagship product, BRIUMVI, is an anti-CD20 monoclonal antibody being developed for adult patients suffering from relapsing forms of multiple sclerosis.

Earnings, Forecast, Therapeutics